VBI Vaccines Inc. (VBIV) Analysts See $-0.25 EPS; WESFARMERS LTD ORDINARY SHARES (WFAFF) SI Decreased By 0.71%

Wesfarmers Limited (OTCMKTS:WFAFF) Logo

Analysts expect VBI Vaccines Inc. (NASDAQ:VBIV) to report $-0.25 EPS on February, 8.After having $-0.24 EPS previously, VBI Vaccines Inc.’s analysts see 4.17% EPS growth. The stock increased 3.87% or $0.06 during the last trading session, reaching $1.61. About 41,932 shares traded. VBI Vaccines Inc. (NASDAQ:VBIV) has declined 67.78% since January 11, 2018 and is downtrending. It has underperformed by 67.78% the S&P500. Some Historical VBIV News: 01/05/2018 – VBI Vaccines 1Q-End Cash and Cash Equivalents $58.1M; 01/05/2018 – VBI Vaccines 1Q Loss/Shr 19c; 17/04/2018 – VBI VACCINES: DSMB RECOMMENDS CONTINUATION OF VBI-1901 STUDY; 12/03/2018 VBI Vaccines Announces Voluntary Delisting From the Toronto Stk Exchange; 10/05/2018 – VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine; 12/03/2018 – VBI VACCINES – CO WILL CONTINUE TO HAVE “SIGNIFICANT” OPERATIONAL PRESENCE IN OTTAWA, CANADA; 19/04/2018 – VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-VacĀ® Hepatitis B Vaccine; 17/04/2018 – VBI VACCINES INC – INITIATED ENROLLMENT IN INTERMEDIATE-DOSE ARM OF DOSE-ESCALATION PHASE OF STUDY; 20/04/2018 – DJ VBI VACCINES INC COM, Inst Holders, 1Q 2018 (VBV); 22/05/2018 – Well Leveraged: VBI Vaccines Outlines Clinical Trial Progress

WESFARMERS LTD ORDINARY SHARES (OTCMKTS:WFAFF) had a decrease of 0.71% in short interest. WFAFF’s SI was 433,700 shares in January as released by FINRA. Its down 0.71% from 436,800 shares previously. With 100 avg volume, 4337 days are for WESFARMERS LTD ORDINARY SHARES (OTCMKTS:WFAFF)’s short sellers to cover WFAFF’s short positions. The stock decreased 0.99% or $0.23 during the last trading session, reaching $22.6. About 1,357 shares traded. Wesfarmers Limited (OTCMKTS:WFAFF) has 0.00% since January 11, 2018 and is . It has by 0.00% the S&P500.

More news for Wesfarmers Limited (OTCMKTS:WFAFF) were recently published by: Seekingalpha.com, which released: “Short Woolworths: Competition Threatening Oligopoly And Earnings; It Is Getting Ugly – Seeking Alpha” on January 20, 2016. Seekingalpha.com‘s article titled: “Woolworths Limited Or Wesfarmers Limited: Which Can Give A Better Long-Term Return? – Seeking Alpha” and published on October 01, 2014 is yet another important article.

Wesfarmers Limited engages in the retail, coal mining and production, gas processing and distribution, industrial and safety product distribution, chemicals and fertilizers manufacturing, and investment businesses in Australia, New Zealand, the United Kingdom, and internationally. The company has market cap of $26.64 billion. The firm operates 801 Coles supermarkets; 883 liquor stores under the Liquorland, Vintage Cellars, and First Choice Liquor brands; 89 hotels; 702 convenience outlets; and an online supermarket. It has a 28.94 P/E ratio. It also offers home, car, and landlord insurance products, as well as credit cards; home improvement and outdoor living products through warehouse stores, smaller format stores, trade centers, and frame and truss sites under the Bunnings name; apparel, homewares, and general merchandise through 303 Target stores and 220 Kmart stores, as well as through online; automotive services, repairs, and tires through 251 Kmart Tyre & Auto Service centers; and office products and solutions through Officeworks stores.

More notable recent VBI Vaccines Inc. (NASDAQ:VBIV) news were published by: Seekingalpha.com which released: “VBI Vaccines closes common stock offering – Seeking Alpha” on December 18, 2018, also Nasdaq.com with their article: “Health Care Sector Update for 12/13/2018: VBIV, AGTC, AMPE, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” published on December 13, 2018, Globenewswire.com published: “VBI Vaccines Announces Proposed Public Offering of Common Shares – GlobeNewswire” on December 12, 2018. More interesting news about VBI Vaccines Inc. (NASDAQ:VBIV) were released by: Seekingalpha.com and their article: “VBI Vaccines prices stock offering at $1.40; shares down 3% premarket – Seeking Alpha” published on December 13, 2018 as well as Nasdaq.com‘s news article titled: “ALT Hits New Low, FPRX Down 26% This Month, VBIV Prices Stock Offering – Nasdaq” with publication date: December 13, 2018.

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company has market cap of $156.72 million. The firm offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It currently has negative earnings. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology.